The Latin America, Middle East and Africa Human Microbiome Market is expected to witness market growth of 35.8% CAGR during the forecast period (2022-2028).
The gut microbiota has a considerable impact on the health of its host. These organisms carry out biochemical processes that impact carcinogenesis, tumor formation, and immune treatment response. Continuous intra-abdominal infections, antimicrobial medicines, or both may raise the risk of colorectal cancer. End products generated by the gut microbiota also have an impact on intestinal cell coverage, either stimulating or inhibiting tumorigenesis. Aside from colorectal cancer, the intestinal microbiota has been demonstrated to play a role in extra-intestinal cancers such as hepatocellular carcinoma by allowing organisms to spread to other areas of the body. Additionally, H. pylori is linked to an increased risk of stomach cancer in humans. Fusobacterium and Clostridium are heavily represented in people with stomach cancer. In the case of breast cancer, environmental and host variables have a direct impact on the disease's progression. Bacterial populations, on the other hand, may cause breast cancer. When compared to healthy people, those with breast cancer have higher Bacillus, Staphylococcus, and Enterobacteriaceae in their breast tissue.
In this region, Cardiovascular diseases have a major foothold. According to the National Library of Medicine, cardiovascular disease is the main cause of mortality among Abu Dhabi residents. Despite the tremendous effort and resource investment, this has not improved over time. Over 39% of deaths in people over 45 years old were due to cardiovascular disease. CVD kills more people over the age of 60 than cancer, respiratory disorders, and infectious diseases combined. A bad diet is the major cause of CVD mortality, with one study estimating that the existing diet was responsible for 72% of CVD deaths in the United Arab Emirates (UAE). In the United Arab Emirates, low consumption of whole grains was linked to 22% of CVD-related deaths. Consumption of processed meat, red meat, and sugar-sweetened beverages are further risk factors.
Despite survey participants' understanding of what comprises healthy eating and exercise habits, impediments to lifestyle change abound. Only 3% of the 390 people surveyed in a UAE study with type 2 diabetes fulfilled the standards' weekly requirements for 150 minutes of moderate-intensity aerobic activity or 90 minutes of vigorous aerobic activity. Cultural reasons (29.2%) and a lack of family support (4.1) were the most common reasons reported in that study for not exercising. With the increasing cases of cardiovascular diseases, the requirement for an effective treatment method is increasing. Therefore, the growth of the regional human microbiomes market is increasing due to the fact that they are effective in boosting the effectiveness of prevention and treatment drugs for CVDs.
The Brazil market dominated the LAMEA Human Microbiome Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $19.8 million by 2028. The Argentina market is anticipated to grow at a CAGR of 36.6% during (2022 - 2028). Additionally, The UAE market is expected to showcase a CAGR of 35.5% during (2022 - 2028).
Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
The gut microbiota has a considerable impact on the health of its host. These organisms carry out biochemical processes that impact carcinogenesis, tumor formation, and immune treatment response. Continuous intra-abdominal infections, antimicrobial medicines, or both may raise the risk of colorectal cancer. End products generated by the gut microbiota also have an impact on intestinal cell coverage, either stimulating or inhibiting tumorigenesis. Aside from colorectal cancer, the intestinal microbiota has been demonstrated to play a role in extra-intestinal cancers such as hepatocellular carcinoma by allowing organisms to spread to other areas of the body. Additionally, H. pylori is linked to an increased risk of stomach cancer in humans. Fusobacterium and Clostridium are heavily represented in people with stomach cancer. In the case of breast cancer, environmental and host variables have a direct impact on the disease's progression. Bacterial populations, on the other hand, may cause breast cancer. When compared to healthy people, those with breast cancer have higher Bacillus, Staphylococcus, and Enterobacteriaceae in their breast tissue.
In this region, Cardiovascular diseases have a major foothold. According to the National Library of Medicine, cardiovascular disease is the main cause of mortality among Abu Dhabi residents. Despite the tremendous effort and resource investment, this has not improved over time. Over 39% of deaths in people over 45 years old were due to cardiovascular disease. CVD kills more people over the age of 60 than cancer, respiratory disorders, and infectious diseases combined. A bad diet is the major cause of CVD mortality, with one study estimating that the existing diet was responsible for 72% of CVD deaths in the United Arab Emirates (UAE). In the United Arab Emirates, low consumption of whole grains was linked to 22% of CVD-related deaths. Consumption of processed meat, red meat, and sugar-sweetened beverages are further risk factors.
Despite survey participants' understanding of what comprises healthy eating and exercise habits, impediments to lifestyle change abound. Only 3% of the 390 people surveyed in a UAE study with type 2 diabetes fulfilled the standards' weekly requirements for 150 minutes of moderate-intensity aerobic activity or 90 minutes of vigorous aerobic activity. Cultural reasons (29.2%) and a lack of family support (4.1) were the most common reasons reported in that study for not exercising. With the increasing cases of cardiovascular diseases, the requirement for an effective treatment method is increasing. Therefore, the growth of the regional human microbiomes market is increasing due to the fact that they are effective in boosting the effectiveness of prevention and treatment drugs for CVDs.
The Brazil market dominated the LAMEA Human Microbiome Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $19.8 million by 2028. The Argentina market is anticipated to grow at a CAGR of 36.6% during (2022 - 2028). Additionally, The UAE market is expected to showcase a CAGR of 35.5% during (2022 - 2028).
Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Drugs
- Diagnostic Tests
- Probiotics
- Prebiotics, and
- Others
By Disease Type
- Infectious Diseases
- Endocrine & Metabolic Disorders
- Gastrointestinal Diseases
- Cancer, and
- Others
By Technology
- Genomics
- Proteomics
- Metabolomics
By Application
- Therapeutics
- Diagnostics
By Type
- Microbiome Consortia Transplantation (FMT)
- Peptide
- Live Biotherapeutic Product
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Seres Therapeutics, Inc.
- 4D pharma plc
- OptiBiotix Health Plc
- Synlogic, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Finch Therapeutics Group, Inc.
- Ferring Holdings SA
- Enterome
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Human Microbiome Market by Product
Chapter 4. LAMEA Human Microbiome Market by Disease Type
Chapter 5. LAMEA Human Microbiome Market by Technology
Chapter 6. LAMEA Human Microbiome Market by Application
Chapter 7. LAMEA Human Microbiome Market by Type
Chapter 8. LAMEA Human Microbiome Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Seres Therapeutics, Inc.
- 4D pharma plc
- OptiBiotix Health Plc
- Synlogic, Inc.
- Second Genome, Inc.
- Vedanta Biosciences, Inc.
- Finch Therapeutics Group, Inc.
- Ferring Holdings SA
- Enterome
Methodology
LOADING...
